Big Pharma’s “Collection” Strategy Just Added Its Biggest Piece Yet

Vertex Pharmaceuticals has never made a deal like this before. On 6 July it agreed to pay $10 billion - its largest acquisition ever - for Crinetics Pharmaceuticals, a roughly 100% premium that sent Crinetics’ shares soaring. The prize was Palsonify (paltusotine), the first once-daily oral therapy for acromegaly, plus atumelnant, a Phase III candidate for congenital adrenal hyperplasia. Together, Vertex believes the two could bring in more than $5bn a year at peak. Just as significant is what the deal signals: Vertex, built almost entirely on its depth in cystic fibrosis, is betting its future partly on someone else’s science.

That’s the pattern I’ve been calling a “collection of biotechs” - big pharma building out its pipeline not through internal discovery but by buying the companies that already did the ‘hard’ part. Kyle LaHucik at Endpoints News captured the mood neatly a few days ago: biopharma, in his words, just keeps buying, buying, buying. By his tally, the first half of 2026 produced 45 acquisitions worth a combined $125.5 billion - which looks likely to beat last year’s 61 deals for the full year, and July has already added four more. (Other trackers land on different totals depending on what counts as a “deal” - BioSpace has 52, PitchBook nearer 200 once you include smaller bolt-ons - so I’d treat any single figure as directional rather than gospel. The direction, at least, isn’t in dispute.)

The rest of the week’s haul

Vertex wasn’t dealmaking alone. Ipsen signed twice in a single week: up to $1.75 billion for Kartos Therapeutics and its Phase III myelofibrosis drug navtemadlin, followed almost immediately by roughly $800 million for Memo Therapeutics, whose lead antibody treats BK polyomavirus-associated nephropathy in kidney transplant patients - a nasty, underserved complication with no approved targeted treatment. Novartis added Myricx Bio, a UK antibody-drug conjugate specialist, for up to $1.5 billion - its third deal this year. And United Therapeutics picked up Thymmune Therapeutics for up to $300 million, a smaller bet on regenerative thymic cell therapy for transplant patients.

Different sizes, same logic. None of these companies needed to build acromegaly expertise, ADC chemistry or thymic biology from scratch. They bought it, fully formed, from the biotechs that spent years getting the science right.

Why buy rather than build

I’ve made the underlying case before: on a risk-adjusted basis, acquiring proven or near-proven science tends to beat internal discovery, because you’re paying for assets that have already cleared the parts of drug development where most failure happens. If you want the numbers behind that - success rates by phase, the Amgen-versus-GSK comparison, what a de-risked asset is actually worth - I laid it out in an earlier post, and this week’s deals are a fairly clean illustration of the argument in practice.

But there’s a catch I flagged in that piece and haven’t resolved yet, and it matters more with every deal like this one: buying the science is the easy part. Keeping what made that science good in the first place is the hard part.

What this does to valuations

There’s a second effect worth naming: this pace of dealmaking is quietly repricing risk further back in the pipeline than it used to be. A few years ago, the smart exit for a lot of biotechs was to partner off an asset after decent Phase II data and let a pharma partner carry the pivotal trial risk. Look at what’s just been paid for, though. Kartos was still Phase III, not yet approved, and still fetched $1.75 billion. Memo’s lead antibody is barely out of Phase II and Ipsen is putting up to $800 million behind it. Even Thymmune, earlier-stage and more speculative than either, found a buyer willing to commit up to $300 million. If that pattern holds, running your own Phase II - or pushing on into Phase III rather than out-licensing early - starts to look like a better-compensated bet than it did two years ago. You’re not de-risking the asset purely for someone else’s benefit; you’re capturing more of that de-risking in the price you’re eventually paid.

The obvious counter is survivorship bias: for every Kartos, there’s a Phase III that reads out badly and quietly disappears, and a week of headlines only ever shows you the winners. I’d also guess this compresses unevenly - a well-understood mechanism in a hot area like oncology or endocrinology probably gets rewarded for going longer; a genuinely novel modality with no read-through comparable asset probably doesn’t. But at the margin, with acquirers this hungry, holding an asset one stage longer than you used to is starting to look like the more rational play rather than the riskier one. Worth watching whether valuations for pre-Phase-III biotechs start drifting up even before data reads out, on the assumption that a buyer will be waiting either way.

The bit that actually worries me

Here’s what I actually believe, for what it’s worth: biotechs are good at drug development not despite being small, underfunded and slightly chaotic, but because of it. The founder who’s spent eighteen years on one disease, the team that’s small enough to change course on a Tuesday, the culture that tolerates the sort of expensive failure a public pharma company would never wave through committee - that’s not incidental to the science. It’s a big part of where the science comes from.

Scott Struthers spent nearly eighteen years building Crinetics around endocrine disease before selling to Vertex this week. That kind of focus is exactly the “collection” model is meant to acquire - and exactly what’s hardest to keep alive once a company the size of Vertex owns you. Big pharma is very good at commercialisation, regulatory strategy and capital allocation. It is not obviously good at leaving a newly-acquired team alone to keep being weird and stubborn about the thing it’s good at. (I do believe Lilly might be an outlier, as I covered in my interview with Verve’s Sek Kathiseran.)

None of this week’s deals are old enough to tell us anything yet - Vertex/Crinetics doesn’t even close until Q3. But it’s worth watching: does Crinetics keep some form of independent identity, or does it simply become another line on Vertex’s org chart within eighteen months? Same question for Ipsen’s two targets, bought within days of each other. My hunch, and it’s only a hunch so far, is that deals built to preserve some autonomy - separate sites, retained leadership, backloaded earn-outs like Ipsen structured for Memo - hold onto more of the value they paid for than deals that go straight to full integration. There was nothing sadder than watching Genentech get ‘Roche-d’ in the ‘olden’ days.

Where this leaves things

The collection strategy isn’t a bubble, and it isn’t going away - the incentives (patent cliffs, cash-rich balance sheets, a public market that rewards pipeline more than lab spend) are too strong. But “big pharma is buying a lot of biotechs” is the easy story. The harder, more interesting one is what survives the acquisition besides the molecule. I’ll be tracking that as these deals actually close, and the drugs launch, rather than just when they’re announced.

---

Sources: Endpoints News (Kyle LaHucik), company press releases, BioPharma Dive, BioSpace, and my earlier post on acquiring biotech innovation, linked above.